1. Home
  2. KROS vs FLX Comparison

KROS vs FLX Comparison

Compare KROS & FLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • FLX
  • Stock Information
  • Founded
  • KROS 2015
  • FLX 2013
  • Country
  • KROS United States
  • FLX China
  • Employees
  • KROS N/A
  • FLX N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • FLX
  • Sector
  • KROS Health Care
  • FLX
  • Exchange
  • KROS Nasdaq
  • FLX NYSE
  • Market Cap
  • KROS 558.9M
  • FLX N/A
  • IPO Year
  • KROS 2020
  • FLX 2024
  • Fundamental
  • Price
  • KROS $13.37
  • FLX $3.25
  • Analyst Decision
  • KROS Buy
  • FLX
  • Analyst Count
  • KROS 13
  • FLX 0
  • Target Price
  • KROS $20.63
  • FLX N/A
  • AVG Volume (30 Days)
  • KROS 637.6K
  • FLX 105.9K
  • Earning Date
  • KROS 08-06-2025
  • FLX 05-22-2025
  • Dividend Yield
  • KROS N/A
  • FLX N/A
  • EPS Growth
  • KROS N/A
  • FLX N/A
  • EPS
  • KROS 0.11
  • FLX N/A
  • Revenue
  • KROS $214,713,000.00
  • FLX $595,490,250.00
  • Revenue This Year
  • KROS $5,006.76
  • FLX N/A
  • Revenue Next Year
  • KROS N/A
  • FLX N/A
  • P/E Ratio
  • KROS $123.16
  • FLX N/A
  • Revenue Growth
  • KROS 91657.70
  • FLX N/A
  • 52 Week Low
  • KROS $9.12
  • FLX $2.01
  • 52 Week High
  • KROS $72.37
  • FLX $21.95
  • Technical
  • Relative Strength Index (RSI)
  • KROS 42.27
  • FLX N/A
  • Support Level
  • KROS $13.25
  • FLX N/A
  • Resistance Level
  • KROS $13.99
  • FLX N/A
  • Average True Range (ATR)
  • KROS 0.36
  • FLX 0.00
  • MACD
  • KROS -0.06
  • FLX 0.00
  • Stochastic Oscillator
  • KROS 20.75
  • FLX 0.00

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: